Old Web
English
Sign In
Acemap
>
authorDetail
>
Ken Ogasawara
Ken Ogasawara
Celgene
Medicine
Pharmacokinetics
Pharmacology
Internal medicine
Oncology
5
Papers
38
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT
2020
Biology of Blood and Marrow Transplantation
Carlos Bachier
M. Lia Palomba
Jeremy S. Abramson
Charalambos Andreadis
Alison R. Sehgal
John E. Godwin
Gerhard C. Hildebrandt
Tanya Siddiqi
Don A. Stevens
Thalia Farazi
Ana Kostic
Nikolaus S. Trede
Lei Wang
James Lymp
Tennille Thelen
Ken Ogasawara
David G. Maloney
Show All
Source
Cite
Save
Citations (3)
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
2019
Clinical Pharmacokinectics
Ken Ogasawara
Kathryn Newhall
Stephen E. Maxwell
Justine Dell’Aringa
Vitalina Komashko
Nurgul Kilavuz
Richard Delarue
Myron S. Czuczman
Lars Sternas
Shelonitda Rose
C.L. Beach
Steven Novick
Simon Zhou
Maria Palmisano
Yan Li
Show All
Source
Cite
Save
Citations (8)
Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
2019
The Journal of Clinical Pharmacology
Ken Ogasawara
Kimberly MacGorman
Liangang Liu
Jian Chen
Leonidas N Carayannopoulos
Simon Zhou
Maria Palmisano
Yan Li
Show All
Source
Cite
Save
Citations (4)
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
2019
Cancer Chemotherapy and Pharmacology
Ken Ogasawara
Simon Zhou
Gopal Krishna
Maria Palmisano
Yan Li
Show All
Source
Cite
Save
Citations (14)
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT
2019
Blood
Carlos Bachier
Maria Lia Palomba
Jeremy S. Abramson
Charalambos Andreadis
Alison R. Sehgal
John E. Godwin
Gerhard C. Hildebrandt
Tanya Siddiqi
Don A. Stevens
Thalia Farazi
Ana Kostic
Nikolaus S. Trede
Lei Wang
James Lymp
Tennille Thelen
Ken Ogasawara
David G. Maloney
Show All
Source
Cite
Save
Citations (9)
1